Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.23.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
9.
Stock-Based Compensation

2020 Equity Incentive Plan

The Company’s 2020 Plan was established for granting stock incentive awards to directors, officers, employees and consultants to the Company.

 

Stock Options

During the nine months ended September 30, 2023, the Company granted 86,669 options with a weighted average strike price of $4.28 to purchase common stock to certain employees and non-employee members of the Board of Directors. Employee options vest annually in 3 equal parts over 3 years, whilst Board of Directors' options vest over 1 year. The Company granted 25,000 performance-based options with a weighted average strike price of $4.44 to purchase common stock to certain employees. These options are subject to performance vesting and will vest and become exercisable once the performance conditions have been met. There is no assurance that the performance conditions will be met and therefore some or all of these options may never vest or become exercisable. The total aggregate grant date fair value of all options granted was $338,741.

During the nine months ended September 30, 2022, the Company granted 76,651 options with a weighted average strike price of $5.80 to purchase common stock to certain employees and non-employee members of the Board of Directors. Employee options vest annually in 3 equal parts over 3 years, whilst Board of Directors' options vest over 1 year. The Company granted 62,500 performance-based options with a weighted average strike price of $6.42 to purchase common stock to certain employees. These options are subject to performance vesting and will vest and become exercisable once the performance conditions have been met. There is no assurance that the performance conditions will be met and therefore some or all of these options may never vest or become exercisable. The total aggregate grant date fair value of all options granted was $542,890.

During the three and nine months ended September 30, 2023 and 2022, no defined performance conditions were probable of being met.

Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:

 

 

Three months ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

41,842

 

 

$

32,817

 

 

$

120,718

 

 

$

98,722

 

Selling, general and administrative

 

 

87,939

 

 

 

68,971

 

 

 

257,181

 

 

 

259,062

 

Total stock-based compensation expense

 

$

129,781

 

 

$

101,788

 

 

$

377,899

 

 

$

357,784